<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Usual doses of ICS-formoterol preparations for maintenance and reliever therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Usual doses of ICS-formoterol preparations for maintenance and reliever therapy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Usual doses of ICS-formoterol preparations for maintenance and reliever therapy</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication and dose per actuation</td> <td class="subtitle1">Low-dose</td> <td class="subtitle1">Medium-dose</td> <td class="subtitle1">High-dose</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Budesonide-formoterol MDI (brand names [United States]: Symbicort, Breyna)</td> </tr> <tr> <td class="indent1">80 mcg/4.5 mcg</td> <td> <p>2 inhalations twice daily<sup>*</sup></p> <p><strong>plus</strong></p> 1 to 2 inhalations as needed; some experts use 2 inhalations unless infrequent rescue inhaler use<sup>¶Δ</sup></td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">160 mcg/4.5 mcg</td> <td> <p>1 inhalation twice daily <strong>or</strong> 2 inhalations once daily<sup>*</sup></p> <p><strong>plus</strong></p> 1 inhalation as needed; if symptoms persist after a few minutes, may repeat<sup>¶Δ</sup></td> <td> <p>2 inhalations twice daily</p> <p><strong>plus</strong></p> 1 inhalation as needed; if symptoms persist after a few minutes, may repeat<sup>¶Δ</sup></td> <td> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Budesonide-formoterol DPI<sup>◊</sup> (brand name [Canada]: Symbicort Forte)</td> </tr> <tr> <td class="indent1">100 mcg/6 mcg</td> <td> <p>2 inhalations twice daily<sup>*</sup></p> <p><strong>plus</strong></p> 1 to 2 inhalations as needed; some experts use 2 inhalations unless infrequent rescue inhaler use<sup>¶Δ</sup></td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">200 mcg/6 mcg</td> <td> <p>1 inhalation twice daily <strong>or</strong> 2 inhalations once daily<sup>*</sup></p> <p><strong>plus</strong></p> 1 inhalation as needed; if symptoms persist after a few minutes, may repeat<sup>¶Δ</sup></td> <td> <p>2 inhalations twice daily</p> <p><strong>plus</strong></p> 1 inhalation as needed; if symptoms persist after a few minutes, may repeat<sup>¶Δ</sup></td> <td> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Mometasone-formoterol MDI (brand name: Dulera [United States]; Zenhale [Canada])</td> </tr> <tr> <td class="indent1">100 mcg/5 mcg</td> <td> </td> <td> <p>2 inhalations twice daily</p> <p><strong>plus</strong></p> 1 inhalation as needed; if symptoms persist after a few minutes, may repeat<sup>¶Δ</sup></td> <td> </td> </tr> <tr> <td class="indent1">200 mcg/5 mcg</td> <td> </td> <td> </td> <td> <p>2 inhalations twice daily</p> <p><strong>plus</strong></p> 1 inhalation as needed; if symptoms persist after a few minutes, may repeat<sup>¶Δ</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="4">Beclomethasone [beclometasone]-formoterol DPI<sup>◊</sup> or MDI (not available in United States or Canada, but available elsewhere [sample brand names: Formodual, Fostair, Foster])</td> </tr> <tr> <td class="indent1">100 mcg/6 mcg</td> <td> <p>1 inhalation twice daily<sup>*</sup></p> <p><strong>plus</strong></p> 1 inhalation as needed; if symptoms persist after a few minutes, may repeat<sup>¶Δ</sup></td> <td> <p>2 inhalations twice daily</p> <p><strong>plus</strong></p> 1 inhalation as needed; if symptoms persist after a few minutes, may repeat<sup>¶Δ</sup></td> <td> </td> </tr> <tr> <td class="indent1">200 mcg/6 mcg</td> <td> </td> <td> </td> <td> <p>2 inhalations twice daily</p> <p><strong>plus</strong></p> 1 inhalation as needed; if symptoms persist after a few minutes, may repeat<sup>¶Δ</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="4">Fluticasone propionate-formoterol MDI (not available in United States or Canada, but available elsewhere [sample brand name: Flutiform])</td> </tr> <tr> <td class="indent1">50 mcg/5 mcg</td> <td> <p>2 inhalations twice daily<sup>*</sup></p> <p><strong>plus</strong></p> 1 to 2 inhalations as needed; some experts use 2 inhalations unless infrequent rescue inhaler use<sup>¶Δ</sup></td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">125 mcg/5 mcg</td> <td> </td> <td> <p>2 inhalations twice daily</p> <p><strong>plus</strong></p> 1 inhalation as needed; if symptoms persist after a few minutes, may repeat<sup>¶Δ</sup></td> <td> </td> </tr> <tr> <td class="indent1">250 mcg/10 mcg</td> <td> </td> <td> </td> <td> <p>2 inhalations twice daily</p> <p><strong>plus</strong></p> 1 inhalation as needed; if symptoms persist after a few minutes, may repeat<sup>¶Δ</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">Dose per actuation is according to United States prescribing information, unless otherwise noted, which may differ from how strengths are described in other countries. Consult local product information. Off-label use of ICS-formoterol formulations for MART may affect cost or availability.</div><div class="graphic_footnotes"><p>DPI: dry powder inhaler; ICS: inhaled glucocorticoid (inhaled corticosteroid); MART: maintenance and reliever therapy; MDI: metered-dose inhaler.</p>
<p>* For patients with well-controlled asthma stepping down from low-dose MART, our authors suggest a trial of even lower dose maintenance therapy, achieved by halving the maintenance dose (ie, changing to once daily administration or reducing the number of actuations per dose). Patients with good control on this very low-dose maintenance regimen can be transitioned to anti-inflammatory reliever therapy alone. Refer to related table for more detail on anti-inflammatory reliever therapy dosing.</p>
<p>¶ Maximum total daily dose of maintenance and rescue is 12 inhalations. Do not exceed the maximum number of inhalations per day due to the risk of toxicity from an excess dose of formoterol. In some countries, product labeling includes a maximum total daily dose of eight inhalations. Use of reliever therapy daily or more frequently over a four-week period indicates poor asthma control and should prompt provider evaluation.</p>
<p>Δ For at-home acute exacerbations, one to two inhalations should be taken as needed for initial symptoms. We advise waiting a few minutes between doses, giving the second dose if symptoms persist. One to two inhalations may be repeated every 20 minutes for up to six inhalations in one hour. Over the course of the first hour, the patient can determine (based on action plan or clinician guidance) whether to continue self-care at home or seek additional medical attention. When self-administering an MDI for acute asthma exacerbation, use of a valved holding chamber (for compatible MDIs) and careful attention to technique are recommended.</p>
◊ DPIs contain lactose which may have small amounts of milk protein.</div><div class="graphic_reference">References:
<ol>
<li>National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Revised August 2007 (NIH publication no. 07-4051). Available at: <a href="https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma" target="_blank">https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma</a> (Accessed November 3, 2023).</li>
<li>National Heart, Lung, and Blood Institute. 2020 focused updates to the asthma management guidelines: A report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. December 2020 (NIH publication no. 20-HL-8140). Available at: <a href="https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates" target="_blank">https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates</a> (Accessed November 3, 2023).</li>
<li>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2023. Updated July 2023. Available at: <a href="https://ginasthma.org/2023-gina-main-report/" target="_blank">https://ginasthma.org/2023-gina-main-report/</a> (Accessed November 8, 2023).</li>
<li>Symbicort Forte Turbuhaler. Health Canada-approved product monograph. Revised February 8, 2021. Health Canada. <a href="https://health-products.canada.ca/dpd-bdpp/info?lang=eng&amp;code=72555" target="_blank">https://health-products.canada.ca/dpd-bdpp/info?lang=eng&amp;code=72555</a> (Accessed November 8, 2023).</li>
</ol></div><div id="graphicVersion">Graphic 143330 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
